<DOC>
	<DOCNO>NCT01933997</DOCNO>
	<brief_summary>objective : To assess safety , tolerability pharmacokinetics metadoxine , administer repeat oral dos MG01CI tablet ( 2 X 700 mg metadoxine per administration ) , healthy adult subject . This single center , open-label , repeated-dose study healthy male female volunteer . Subjects undergo screen within 21 day prior first dose assess eligibility participate study . All subject receive 1400 mg metadoxine two MG01CI oral extended-release tablet , administer daily five consecutive day . Blood sample metadoxine ( consist two component : pyrrolidone-5-carboxylate pyridoxine identify plasma concentration assay ) drawn designate time point , describe pharmacokinetic ( PK ) evaluation section . The subject remain confined unit 6 day first dose . A study termination visit take place 10-12 day last dosing day . The subject monitor safety , AEs ( Adverse event ) record throughout study .</brief_summary>
	<brief_title>A Phase 1 Study Assess Pharmacokinetics Metadoxine ( MG01CI ) 1400 mg , Administered Healthy Volunteers</brief_title>
	<detailed_description>This single center , open-label , repeated-dose study healthy male female volunteer . The overall study design outline Figure 3 . Sixteen ( 16 ) healthy subject participate study ( le 7 male less 7 female ) . The study comprise screen period ( 21 day first dose ) , dose period subject receive daily single oral administration 2 tablet , contain 700 mg metadoxine ( total 1400 mg ) five consecutive day , EOS/Follow-up visit 10-12 day follow last dosing . Subjects instruct arrive CRC ( clinical research center ) clinic even dose period ( Day 0 ) . Check-in procedure perform outlined Schedule Events . The subject remain CRC approximately 7 day . Drugs administer 10-hour fast 240 mL water . Drugs administer subject bed sit angle least 45 degree , , Dosing Days 1 ( first dosing ) 5 ( last dosing ) remain next 4 hour . There 24-hour interval dosing . On Dosing Days 1 ( first dosing ) 5 ( last dosing ) subject continue fast next 4 hour post-dose , time meal provide . Water allow freely one hour , one hour dosing . Standardized meal provide accord schedule Blood PK analysis metadoxine component ( pyrrolidone-5-carboxylate L-pyroglutamic acid pyridoxine ) sample serially follow dose per schedule PK Evaluation Subjects discharge CRC approximately 24 hour last dose . There end study ( EOS ) / follow-up visit ass safety 10-12 day follow last dosing . Analysis blood sample collect clinical facility determine plasma concentration metadoxine conduct Avogadro , `` Parc de Genibrat 31470 Fontenilles France '' .</detailed_description>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . Healthy men woman 18 45 year ( inclusive ) age . 2 . Subjects provide write informed consent participate study . 3 . Body Mass Index ( BMI ) 19 29 kg/m2 ( inclusive ) . 4 . Nonsmoking use tobacco nicotine product ( declaration ) period least 6 month prior screen visit negative urine cotinine test rule active smoke screen visit . 5 . Subjects general good health opinion investigator determine medical history , vital sign physical examination . 6 . Blood pressure heart rate within normal limit ( blood pressure : systolic 90140 mmHg ; diastolic 5090 mmHg , heart rate 50100 beat per minute ( bpm ) . 7 . Female subject must negative serum pregnancy test screen willing able use medically acceptable method birth control declare abstain sexual intercourse , screen visit study termination visit surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) postmenopausal . Postmenopausal woman define woman menstruation cessation 12 consecutive month prior sign inform consent form . 8 . Electrocardiogram ( ECG ) clinically significant Investigator assessment discretion case borderline result allow . 9 . Negative HIV , Hepatitis B Hepatitis C serology test screen . 10 . No clinically significant abnormality hematology , blood chemistry , urinalysis lab test screen . 11 . No known history alcohol drug abuse . Negative urinary drug abuse screen determine within 21 day start study ( Screening checkin visit ) . 12 . Subjects must able understand requirement study must willing comply requirement study . 1 . Known history significant medical disorder , investigator 's judgment contraindicate administration study medication . 2 . Any clinically significant abnormality upon physical examination clinical laboratory test screen visit . 3 . Use prescription overthecounter ( OTC ) medication , include vitamin herbal dietary supplement within 14 day prior first dosing . Paracetamol symptomatic relief pain allow 24 hour prior first study drug administration . 4 . Drug alcohol abuse . 5 . Known hypersensitivity and/or allergy drug . 6 . Any acute illness ( e.g . acute infection ) within 48 hour prior first study drug administration , consider significance investigator . 7 . Participation another clinical trial drug receive within 3 month prior dose ( calculate previous study 's last dosing date ) . 8 . Subjects donate blood three month receive blood plasma derivative six month precede study drug administration . 9 . Subjects inability communicate well investigator CRC staff ( i.e. , language problem , poor mental development impair cerebral function ) . 10 . Inability fast consume food provide study ( include know food allergy food restriction ) . 11 . Pregnant currently lactate woman . 12 . Subjects noncooperative unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>metadoxine</keyword>
</DOC>